CLINICAL TRIALS PROFILE FOR OLYSIO
✉ Email this page to a colleague
All Clinical Trials for OLYSIO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02118597 ↗ | An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients | Terminated | Hoffmann-La Roche | 2014-05-01 | This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with genotype 1 chronic hepatitis C (CHC) infection. Dosing and treatment duration were at the discretion of the investigator in accordance with local clinical practice and local labeling. Participants were to be observed for the duration of their triple combination therapy and for up to 24 weeks thereafter. | |
| NCT02168361 ↗ | The SIM-SOF Trial for Hepatitis C | Completed | Center For Hepatitis C, Atlanta, GA | Phase 4 | 2013-12-01 | Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without Ribavirin. |
| NCT02206932 ↗ | A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C | Withdrawn | Janssen Scientific Affairs, LLC | Phase 4 | 2014-08-01 | This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses. |
| NCT02206932 ↗ | A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C | Withdrawn | University of California, San Francisco | Phase 4 | 2014-08-01 | This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses. |
| NCT02455167 ↗ | Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis | Terminated | Janssen Scientific Affairs, LLC | Phase 3 | 2015-05-01 | 1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV). 2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OLYSIO
Condition Name
Clinical Trial Locations for OLYSIO
Trials by Country
Clinical Trial Progress for OLYSIO
Clinical Trial Phase
Clinical Trial Sponsors for OLYSIO
Sponsor Name
